Опухоли головы и шеи (Apr 2024)
“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use
- E. V. Borodavina,
- A. Yu. Shurinov,
- S. I. Kutukova,
- E. N. Nedozorova,
- A. V. Malanchuk,
- Yu. V. Semenchenko,
- S. M. Povarkov,
- K. V. Narovenkova,
- A. V. Khodkevich,
- Yu. V. Komoza,
- K. A. Kofanova,
- S. P. Dmitriev,
- E. B. Vasilyeva,
- S. A. Shikhamirova,
- M. N. Gorshenina,
- L. N. Volodina,
- O. A. Snezhko,
- O. A. Stativko,
- D. V. Xenodokhov,
- Yu. G. Dzhemageldieva,
- A. I. Khryapa,
- D. M. Ulimaeva,
- E. M. Dagba,
- M. V. Volkonsky,
- V. M. Filippova,
- M. O. Skorina,
- O. V. Romanchuk,
- I. I. Andrienko,
- M. V. Shorin,
- A. A. Ishchenko,
- R. A. Dumbrava,
- M. B. Bolieva,
- F. V. Tsarakhova,
- Z. A. Gojieva,
- S. S. Dzhamirzaeva,
- P. Z. Aidaeva,
- M. O. Maximov,
- I. S. Usoltseva,
- A. O. Milyukova,
- O. V. Toporkova,
- V. D. Sychev,
- S. A. Rudakov,
- S. T. Sagdieva,
- M. A. Klochikhin,
- V. V. Molokova,
- R. A. Skotnikov,
- E. N. Yeremina,
- Yu. A. Panaseikin,
- Ya. A. Tyugina,
- Yu. I. Murzina,
- S. O. Podvyaznikov
Affiliations
- E. V. Borodavina
- A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
- A. Yu. Shurinov
- A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
- S. I. Kutukova
- Academician I.P. Pavlov First St. Petersburg State Medical University
- E. N. Nedozorova
- Republican Clinical Oncological Dispensar, Ministry of Health of the Chuvash Republic
- A. V. Malanchuk
- Voronezh Regional Clinical Oncological Dispensary
- Yu. V. Semenchenko
- Voronezh Regional Clinical Oncological Dispensary
- S. M. Povarkov
- Voronezh Regional Clinical Oncological Dispensary
- K. V. Narovenkova
- Bryansk Regional Oncological Dispensary
- A. V. Khodkevich
- Bryansk Regional Oncological Dispensary
- Yu. V. Komoza
- Bryansk Regional Oncological Dispensary
- K. A. Kofanova
- Scientific Research Institute of Clinical Oncology Nizhny Novgorod Regional Clinical Oncological Dispensary
- S. P. Dmitriev
- Scientific Research Institute of Clinical Oncology Nizhny Novgorod Regional Clinical Oncological Dispensary
- E. B. Vasilyeva
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
- S. A. Shikhamirova
- Republican Cancer Center
- M. N. Gorshenina
- Republican Clinical Oncological Dispensary
- L. N. Volodina
- Regional Clinical Oncological Dispensary
- O. A. Snezhko
- Oncological Dispensary
- O. A. Stativko
- City Cancer Hospital No. 1, Moscow Healthcare Department
- D. V. Xenodokhov
- Clinical Oncological Dispensary No. 1, Ministry of Health of the Krasnodar Territory
- Yu. G. Dzhemageldieva
- Clinical Oncological Dispensary No. 1, Ministry of Health of the Krasnodar Territory
- A. I. Khryapa
- Leningrad Regional Clinical Hospital
- D. M. Ulimaeva
- Leningrad Regional Clinical Hospital
- E. M. Dagba
- Leningrad Regional Clinical Hospital
- M. V. Volkonsky
- Moscow Cancer Hospital No. 62, Moscow Healthcare Department
- V. M. Filippova
- Moscow Cancer Hospital No. 62, Moscow Healthcare Department
- M. O. Skorina
- Moscow Cancer Hospital No. 62, Moscow Healthcare Department
- O. V. Romanchuk
- Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department
- I. I. Andrienko
- Klinsk Hospital
- M. V. Shorin
- Naro-Fominsk Hospital
- A. A. Ishchenko
- Regional Oncological Dispensary
- R. A. Dumbrava
- Primorsk Regional Oncological Dispensary
- M. B. Bolieva
- Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
- F. V. Tsarakhova
- Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
- Z. A. Gojieva
- Republican Oncological Dispensary, Ministry of Health of the Republic of North Ossetia–Alania
- S. S. Dzhamirzaeva
- Republican Oncological Dispensary
- P. Z. Aidaeva
- Republican Oncological Dispensary
- M. O. Maximov
- Republican Oncological Dispensary, Ministry of Health of the Republic of Khakassia
- I. S. Usoltseva
- Sakhalin Regional Clinical Oncological Dispensary
- A. O. Milyukova
- Sakhalin Regional Clinical Oncological Dispensary
- O. V. Toporkova
- Tambov Regional Oncological Clinical Dispensary
- V. D. Sychev
- Tambov Regional Oncological Clinical Dispensary
- S. A. Rudakov
- Tambov Regional Oncological Clinical Dispensary
- S. T. Sagdieva
- Regional Clinical Oncological Hospital
- M. A. Klochikhin
- Regional Clinical Oncological Hospital
- V. V. Molokova
- Zabaikalsky Regional Oncological Dispensary
- R. A. Skotnikov
- Tula Regional Clinical Oncological Dispensary
- E. N. Yeremina
- Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky
- Yu. A. Panaseikin
- A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of the Russia
- Ya. A. Tyugina
- Ivanovo Regional Oncological Dispensary
- Yu. I. Murzina
- Oncological Dispensary
- S. O. Podvyaznikov
- N.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
- DOI
- https://doi.org/10.17650/2222-1468-2023-13-4-73-82
- Journal volume & issue
-
Vol. 13,
no. 4
pp. 73 – 82
Abstract
Introduction. The multikinase inhibitors have demonstrated high clinical efficacy in treatment of the radioiodine refractory differentiated thyroid cancer. At the same time, the inclusion criteria in the studies has reflected a minimum set of characteristics important for beginning of use of these drugs and an approach that takes into account the tumor progression rate (the volume doubling time) in the absence of clinical manifestations of the disease that have made it possible to individualize the start of therapy. Aim. To describe and evaluate the barriers and drivers of use the “watch and wait” approach by Russian oncologists in treatment of the radioiodine refractory thyroid cancer. Materials and methods. We conducted 35 structured interviews with oncologists observing patients after radioiodine therapy in order to evaluate the “watch and wait” approach. unfortunately, data on use and prevalence of this approach in Russia are limited. The present study involved the use of deductive content analysis as well as analysis of implementation model of clinical guidelines and included investigation of issue of implementation of the “watch and wait” approach to current practice of therapy for radioiodine refractory differentiated thyroid cancer. One of the main tasks was to determine the influence of external factors on the treatment of this category of patients. Conclusion. Barriers and drivers of using “watch and wait” approach in the treatment of differentiated radioiodine refractory thyroid cancer are identified at several levels. for wide use of this approach, it is necessary to involve oncologists taking into account their attitude regarding changes in routine practices, patient expectations and to obtain additional data regarding its long-term effectiveness.
Keywords